Related Experiment Videos
Systemic fungal infections: major problems in cancer patients
1Leukaemia Unit, Royal Marsden Hospital, Sutton, Surrey, UK.
Indian Journal of Cancer
|September 1, 1994
Abstract:
Over the last decade, with increasing use of aggressive chemotherapy and bone marrow transplantation in the treatment of cancer, fungi have emerged as a major pathogen. The prognosis of established systemic fungal infections remains poor, but newer antifungal drugs such as fluconazole are changing the outlook of therapy and prophylaxis considerably.
Insights
Systemic fungal infections are a growing threat in cancer patients undergoing chemotherapy or bone marrow transplantation. Newer antifungal drugs like fluconazole offer improved treatment and prevention strategies, enhancing patient outcomes.
Area of Science:
- Mycology
- Oncology
- Infectious Diseases
Background:
- Cancer therapies like chemotherapy and bone marrow transplantation increase susceptibility to fungal infections.
- Systemic fungal infections in immunocompromised patients historically have a poor prognosis.
Purpose of the Study:
- To highlight the emerging role of fungi as significant pathogens in cancer care.
- To discuss the impact of novel antifungal agents on managing these infections.
Main Methods:
- Review of current literature on fungal infections in cancer patients.
- Analysis of treatment outcomes with newer antifungal drugs.
Main Results:
- Fungal infections are increasingly prevalent in patients receiving aggressive cancer treatments.
- Antifungal drugs, including fluconazole, are demonstrating efficacy in therapy and prophylaxis.
Conclusions:
- The rise of aggressive cancer treatments necessitates vigilance against opportunistic fungal infections.
- Advancements in antifungal pharmacotherapy are improving the prognosis for cancer patients with systemic fungal infections.